Malecare Prostate Cancer Support Group

Uncategorized

Europe Awaits Xtandi – A Positive CHMP Opinion on the Clearance of Enzalutamide In the Pre-Chemotherapy Stage of Prostate Cancer

Some good news for my European brothers, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adapted a positive opinion in support of the label expansion of enzalutamide (XTANDI) to include the treatment of men with metastatic castrate resistant prostate cancer (MCRPC) who are asymptomatic or mildly symptomatic after the failure [...]

By |2014-10-24T09:52:48-04:00October 24th, 2014|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, enzalutamide, Uncategorized, Xtandi|0 Comments
Read More

Updated Overall Survival (OS) Data from a Phase 3 Trial of Ipilimumab (Ipi) vs. Placebo in Men Post Chemotherapy

In a poster presentation at the recent European Society of Medical Oncologists (ESMO) there was a very interesting poster presented updating a phase 3 clinical trial (CA184-043) which evaluated the overall survival (OS) with radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. This trial did not meet its endpoint [...]

By |2017-10-19T10:47:45-04:00October 23rd, 2014|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Combination Therapy, Drugs & Treatments, ESMO, immunotherapy, ipilimumab, Radiotherapy, Uncategorized, vaccines|0 Comments
Read More

Bayer Issues a Formal Statement About the Halting of the Production of Xofigo (Radium Ra 223 Dichloride)

Its day 20 since Xofigo production stopped. How are you? Please email Joel at joel@malecare.org about how the Xofigo shutdown has affected your life. Bayer has issued a public statement about the shortage of Xofigo (radium Ra 223 dichloride). After reviewing their statement I find that there is no new information that we haven’t already [...]

By |2020-02-04T11:54:39-05:00October 22nd, 2014|Advanced Prostate Cancer, Drugs & Treatments, radiopharmaceuticals, Uncategorized, Xofigo|0 Comments
Read More

Lack of PSA Decline as an Independent Predictor of Biochemical Failure Post Salvage Radiation Therapy

It would be of great advantage to us if we were able to improve the early detection of responders to salvage external beam radiotherapy (RT) after failed radical prostatectomy (RP). Early detection would allow us to make earlier treatment decisions which should provide for better results. In an attempt to better improve our understanding of [...]

By |2014-10-20T16:06:11-04:00October 20th, 2014|Advanced Prostate Cancer, Bio Chemical Recurrence, biomarkers, Drugs & Treatments, prognostic tools, Radiotherapy, salvage therapy, Uncategorized, Understanding APC|0 Comments
Read More
Go to Top